Resident’s Forum
Vaccine for the Prevention of Herpes Zoster
FR-Nueva vacuna recombinante para la prevención del herpes zóster
D. Morgado-Carrasco
, X. Fustà-Novell, P. Giavedoni
Corresponding author
Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain
Read
4843
Timeswas read the article
1727
Total PDF
3116
Total HTML
Share statistics
array:25 [ "pii" => "S1578219019303506" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.06.030" "estado" => "S300" "fechaPublicacion" => "2020-01-01" "aid" => "2216" "copyright" => "AEDV" "copyrightAnyo" => "2019" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2020;111:67-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:20 [ "pii" => "S0001731019301814" "issn" => "00017310" "doi" => "10.1016/j.ad.2018.06.020" "estado" => "S300" "fechaPublicacion" => "2020-01-01" "aid" => "2216" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2020;111:67-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 39 "formatos" => array:2 [ "HTML" => 24 "PDF" => 15 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Foro de Residentes</span>" "titulo" => "FR-Nueva vacuna recombinante para la prevención del herpes zóster" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "67" "paginaFinal" => "68" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "RF-New Recombinant Vaccine for the Prevention of Herpes Zoster" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "D. Morgado-Carrasco, X. Fustà-Novell, P. Giavedoni" "autores" => array:3 [ 0 => array:2 [ "nombre" => "D." "apellidos" => "Morgado-Carrasco" ] 1 => array:2 [ "nombre" => "X." "apellidos" => "Fustà-Novell" ] 2 => array:2 [ "nombre" => "P." "apellidos" => "Giavedoni" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219019303506" "doi" => "10.1016/j.adengl.2018.06.030" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019303506?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731019301814?idApp=UINPBA000044" "url" => "/00017310/0000011100000001/v3_202009190630/S0001731019301814/v3_202009190630/es/main.assets" ] ] "itemSiguiente" => array:20 [ "pii" => "S1578219019301088" "issn" => "15782190" "doi" => "10.1016/j.adengl.2019.03.014" "estado" => "S300" "fechaPublicacion" => "2020-01-01" "aid" => "2122" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2020;111:69" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Images in Dermatology</span>" "titulo" => "Alopecia in Meralgia Paresthetica" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "69" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Alopecia en meralgia parestésica" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:6 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 835 "Ancho" => 905 "Tamanyo" => 147455 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "B. Monteagudo, S. Peña-López, D. Santos-García" "autores" => array:3 [ 0 => array:2 [ "nombre" => "B." "apellidos" => "Monteagudo" ] 1 => array:2 [ "nombre" => "S." "apellidos" => "Peña-López" ] 2 => array:2 [ "nombre" => "D." "apellidos" => "Santos-García" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731018305489" "doi" => "10.1016/j.ad.2018.03.026" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018305489?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019301088?idApp=UINPBA000044" "url" => "/15782190/0000011100000001/v2_202004200619/S1578219019301088/v2_202004200619/en/main.assets" ] "itemAnterior" => array:20 [ "pii" => "S1578219019303427" "issn" => "15782190" "doi" => "10.1016/j.adengl.2019.11.001" "estado" => "S300" "fechaPublicacion" => "2020-01-01" "aid" => "2237" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2020;111:65-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case for Diagnosis</span>" "titulo" => "Pitting Edema of the Face, An Important Differential Diagnosis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "65" "paginaFinal" => "66" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Edema facial con fóvea, un importante diagnóstico diferencial" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 755 "Ancho" => 506 "Tamanyo" => 67906 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Facial pitting erythematous edema, predominantly on the left side.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J.G. Chalela, M.I. González, M.F. Ordóñez Rubiano" "autores" => array:3 [ 0 => array:2 [ "nombre" => "J.G." "apellidos" => "Chalela" ] 1 => array:2 [ "nombre" => "M.I." "apellidos" => "González" ] 2 => array:2 [ "nombre" => "M.F." "apellidos" => "Ordóñez Rubiano" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731019302236" "doi" => "10.1016/j.ad.2018.04.018" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731019302236?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019303427?idApp=UINPBA000044" "url" => "/15782190/0000011100000001/v2_202004200619/S1578219019303427/v2_202004200619/en/main.assets" ] "en" => array:16 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Resident’s Forum</span>" "titulo" => "Vaccine for the Prevention of Herpes Zoster" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "67" "paginaFinal" => "68" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "D. Morgado-Carrasco, X. Fustà-Novell, P. Giavedoni" "autores" => array:3 [ 0 => array:4 [ "nombre" => "D." "apellidos" => "Morgado-Carrasco" "email" => array:1 [ 0 => "morgado@clinic.cat" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "X." "apellidos" => "Fustà-Novell" ] 2 => array:2 [ "nombre" => "P." "apellidos" => "Giavedoni" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "FR-Nueva vacuna recombinante para la prevención del herpes zóster" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Herpes zoster is caused by reactivation of the varicella zoster virus, which is characterized by a generally localized and painful vesicular skin rash. Its incidence has increased in recent decades. The most frequent complication is postherpetic neuralgia, which affects around 18% of patients with herpes zoster and may cause disabling pain. The incidence of both conditions clearly increases with age. Postherpetic neuralgia affects more than 30% of persons with herpes zoster aged >79 years. The attenuated varicella zoster virus vaccine (aVZV) has an efficacy of 51% for prevention of herpes zoster; this efficacy decreases with age. The vaccine is contraindicated in immunocompromised patients and approved by the United States Food and Drug Administration (FDA) for this indication in immunocompetent patients aged ≥50 years.</p><p id="par0010" class="elsevierStylePara elsevierViewall">The FDA recently approved a new recombinant vaccine for treatment of herpes zoster (rVZV) (Shingrix, GlaxoSmithKline). rVZV contains recombinant glycoprotein E of the varicella zoster virus, together with the adjuvant AS01<span class="elsevierStyleInf">B</span>, and is administered in 2 subcutaneous injections separated by 2–6 months (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). The efficacy of rVZV was evaluated in 2 phase 3 randomized, placebo-controlled clinical trials (ZOE-50<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> and ZOE-70<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a>). Median follow-up was longer than 3 years in both trials. ZOE-50 included 15 411 patients aged ≥50 years and reported 6 cases of herpes zoster in the vaccinated group compared with 210 in the placebo group. Overall efficacy in the prevention of herpes zoster was 97.2% (95% CI, 93.7–99.0%; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>.001).<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> ZOE-70 included 13 900 patients aged ≥70 years. Efficacy was 89.8% (95% CI, 84.2–93.7%; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>.001) for prevention of herpes zoster and 88.8% (95% CI, 68.7–97.1%; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>.001) for prevention of postherpetic neuralgia.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> A pooled analysis of both studies showed that efficacy was 93.7% (95% CI, 59.5–99.9%) for the prevention of post–herpes zoster complications other than postherpetic neuralgia, i.e., disseminated herpes zoster, secondary vasculitis, encephalic vascular accident, and ophthalmic, neurologic, and visceral disease.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> In both studies, the frequency of adverse events was similar in the vaccination and placebo groups. The most frequent adverse events were injection site pain, myalgia, and fatigue.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">rVZV has proven more successful than aVZV for prevention of herpes zoster and postherpetic neuralgia. Furthermore, the cost-effectiveness analysis favored rVZV over aVZV.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> Consequently, the Advisory Committee on Immunization Practices in the United States recently recommended rVZV for immunocompetent patients aged ≥50 years, even in those previously vaccinated with aVZV and those who have had herpes zoster.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> Evidence remains insufficient to recommend rVZV in immunocompetent patients or patients who are receiving immunosuppressive treatment with prednisone ≥20 mg/d, although it could, in theory, be administered.</p><p id="par0020" class="elsevierStylePara elsevierViewall">rVZV is an efficacious and safe alternative for prevention of herpes zoster and postherpetic neuralgia and should be recommended in adults. It could thus help to reduce the morbidity associated with these conditions.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2018-05-18" "fechaAceptado" => "2018-06-25" "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1223716" "palabras" => array:6 [ 0 => "Herpes zoster vaccine" 1 => "Recombinant vaccine" 2 => "Adyuvanted" 3 => "Herpes zoster" 4 => "Post herpetic neuralgia" 5 => "Shingrix®" ] ] ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Please cite this article as: Morgado-Carrasco D, Fustà-Novell X, Giavedoni P. FR-Nueva vacuna recombinante para la prevención del herpes zóster. Actas Dermosifiliogr. 2020;111:67–68.</p>" ] ] "multimedia" => array:1 [ 0 => array:9 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "fuente" => "Source: Dooling et al.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a>" "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0015" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Abbreviations: HZ, herpes zoster; HZ/su, HZ/subunit; aVZV, attenuated varicella zoster vaccine.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Composition \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Administration \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Target Patients \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Special Situations \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Coadministration \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Recombinant glycoprotein E of varicella zoster virus, which is essential for viral replication and propagation and is the target of the specific immune response. Adjuvant AS01<span class="elsevierStyleInf">B</span> (HZ/su), which promotes a marked and prolonged CD4 response to recombinant proteins. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Two subcutaneous injections separated by 2–6<span class="elsevierStyleHsp" style=""></span>mo. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Adults aged ≥50 y, even if they have been previously vaccinated with aVZV or affected by HZ. Serological screening for varicella is not recommended. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Not currently recommended for pregnant women. Patients with chronic diseases (chronic kidney failure, diabetes mellitus, chronic lung disease) should be vaccinated. Patients experiencing an acute episode of HZ should not be vaccinated until resolution of the acute phase. Patients receiving prednisone <20<span class="elsevierStyleHsp" style=""></span>mg/d should be vaccinated. Immunocompromised patients or patients receiving prednisone ≥20<span class="elsevierStyleHsp" style=""></span>mg/d should not be vaccinated<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Can be coadministered with other vaccines in adults. Should be injected at different sites. \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2275671.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Evidence remains insufficient to recommend vaccination in immunocompetent patients, although it is possible in theory.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Characteristics and Indications of the Recombinant Herpes Zoster Vaccine (Shingrix).</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H. Lal" 1 => "A.L. Cunningham" 2 => "O. Godeaux" 3 => "R. Chlibek" 4 => "J. Diez-Domingo" 5 => "S.-J. Hwang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1501184" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2015" "volumen" => "372" "paginaInicial" => "2087" "paginaFinal" => "2096" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25916341" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.L. Cunningham" 1 => "H. Lal" 2 => "M. Kovac" 3 => "R. Chlibek" 4 => "S.-J. Hwang" 5 => "J. Díez-Domingo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "N Engl J Med" "fecha" => "2016" "volumen" => "375" "paginaInicial" => "1019" "paginaFinal" => "1032" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Kovac" 1 => "H. Lal" 2 => "A.L. Cunningham" 3 => "M.J. Levin" 4 => "R.W. Johnson" 5 => "L. Campora" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.vaccine.2018.02.029" "Revista" => array:6 [ "tituloSerie" => "Vaccine" "fecha" => "2018" "volumen" => "36" "paginaInicial" => "1537" "paginaFinal" => "1541" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29463421" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "P. Le" 1 => "M.B. Rothberg" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jamainternmed.2017.7431" "Revista" => array:6 [ "tituloSerie" => "JAMA Intern Med" "fecha" => "2018" "volumen" => "178" "paginaInicial" => "248" "paginaFinal" => "258" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29297049" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K.L. Dooling" 1 => "A. Guo" 2 => "M. Patel" 3 => "G.M. Lee" 4 => "K. Moore" 5 => "E.A. Belongia" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.15585/mmwr.mm6703a5" "Revista" => array:6 [ "tituloSerie" => "MMWR Morb Mortal Wkly Rep" "fecha" => "2018" "volumen" => "67" "paginaInicial" => "103" "paginaFinal" => "108" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29370152" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000011100000001/v2_202004200619/S1578219019303506/v2_202004200619/en/main.assets" "Apartado" => array:4 [ "identificador" => "34945" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Resident's Forum" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000011100000001/v2_202004200619/S1578219019303506/v2_202004200619/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019303506?idApp=UINPBA000044" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 9 | 7 | 16 |
| 2024 October | 105 | 50 | 155 |
| 2024 September | 89 | 31 | 120 |
| 2024 August | 135 | 57 | 192 |
| 2024 July | 109 | 32 | 141 |
| 2024 June | 103 | 67 | 170 |
| 2024 May | 111 | 41 | 152 |
| 2024 April | 131 | 27 | 158 |
| 2024 March | 111 | 32 | 143 |
| 2024 February | 95 | 32 | 127 |
| 2024 January | 95 | 32 | 127 |
| 2023 December | 75 | 17 | 92 |
| 2023 November | 111 | 27 | 138 |
| 2023 October | 67 | 21 | 88 |
| 2023 September | 78 | 29 | 107 |
| 2023 August | 44 | 20 | 64 |
| 2023 July | 65 | 31 | 96 |
| 2023 June | 73 | 22 | 95 |
| 2023 May | 68 | 30 | 98 |
| 2023 April | 56 | 18 | 74 |
| 2023 March | 66 | 26 | 92 |
| 2023 February | 41 | 20 | 61 |
| 2023 January | 47 | 27 | 74 |
| 2022 December | 42 | 34 | 76 |
| 2022 November | 40 | 27 | 67 |
| 2022 October | 33 | 22 | 55 |
| 2022 September | 24 | 38 | 62 |
| 2022 August | 56 | 35 | 91 |
| 2022 July | 40 | 47 | 87 |
| 2022 June | 42 | 28 | 70 |
| 2022 May | 32 | 36 | 68 |
| 2022 April | 37 | 30 | 67 |
| 2022 March | 42 | 51 | 93 |
| 2022 February | 45 | 38 | 83 |
| 2022 January | 26 | 33 | 59 |
| 2021 December | 23 | 40 | 63 |
| 2021 November | 40 | 46 | 86 |
| 2021 October | 44 | 60 | 104 |
| 2021 September | 44 | 45 | 89 |
| 2021 August | 26 | 30 | 56 |
| 2021 July | 30 | 23 | 53 |
| 2021 June | 40 | 19 | 59 |
| 2021 May | 44 | 31 | 75 |
| 2021 April | 64 | 64 | 128 |
| 2021 March | 48 | 26 | 74 |
| 2021 February | 40 | 21 | 61 |
| 2021 January | 33 | 21 | 54 |
| 2020 December | 27 | 29 | 56 |
| 2020 November | 31 | 22 | 53 |
| 2020 October | 25 | 16 | 41 |
| 2020 September | 28 | 15 | 43 |
| 2020 August | 39 | 19 | 58 |
| 2020 July | 20 | 13 | 33 |
| 2020 June | 21 | 20 | 41 |
| 2020 May | 37 | 19 | 56 |
| 2020 April | 46 | 24 | 70 |
| 2020 March | 21 | 9 | 30 |
| 2020 February | 2 | 0 | 2 |
Show all
